Actively Recruiting

Age: 18Years - 75Years
All Genders
ID05867901

Clinical Research of Drug Holiday Based on MRD Detection in Gastrointestinal Stromal Tumor Patients at High Risk of Recurrence

Led by Peking University People's Hospital · Updated on 2023-05-31

40

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating the use of minimal residual disease (MRD) detection through liquid biopsy to monitor postoperative recurrence and guide treatment in patients with high-risk gastrointestinal stromal tumors (GIST). The study focuses on patients who have undergone surgery and long-term treatment with the drug imatinib, aiming to evaluate whether a "drug holiday" approach, where medication is paused based on MRD results, affects progression-free survival, overall survival, and the development of drug resistance. This observational trial also examines the response to restarting imatinib if the disease progresses after drug withdrawal. This one-arm observational clinical trial follows a single group of high-risk GIST patients who have completed at least three years of imatinib after surgery with disease control and negative baseline MRD. Participants will stop taking imatinib and be monitored using MRD detection and imaging to observe recurrence or progression. If disease progression occurs, imatinib may be restarted. The study period includes up to three years of follow-up after entering the drug holiday phase to assess survival outcomes, drug re-use rates, genetic mutation changes, and comparison of MRD with imaging results. Participants will undergo regular clinical and imaging evaluations, along with blood tests to detect circulating tumor DNA, which helps track MRD status. Researchers will measure progression-free survival from the start of drug withdrawal until disease progression, as well as overall survival up to three years. The study requires patients to cooperate with follow-up visits, provide clinical and imaging data, and allow use of their test results for ongoing research. This careful monitoring aims to understand the potential benefits and risks of pausing imatinib based on MRD findings in high-risk GIST patients.

CONDITIONS

Brief Title

Clinical Research of Drug Holiday Based on MRD Detection in GIST Patients at High Risk of Recurrence

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age between 18 and 75 years
  • Primary and metastatic lesions surgically removed with R0 or R1 resection
  • Clinically diagnosed with high recurrence risk GIST confirmed by pathology after surgery
  • Completed 3 years of imatinib adjuvant therapy with no visible lesions on imaging
  • Negative baseline liquid biopsy for circulating tumor DNA (ctDNA)
  • No primary imatinib resistant mutations detected by genetic testing
  • Performance status (PS) score of 0-1 and expected survival longer than 4 months
  • Willingness to stop drug use, cooperate with follow-up, and provide clinical and imaging data with informed consent
Not Eligible

You will not qualify if you...

  • Surgical tumor tissue samples not available
  • Not receiving assigned treatment or changing therapy before disease progression
  • Unable to cooperate with follow-up visits as scheduled
  • Unable to undergo required imaging assessments
  • Other conditions deemed inappropriate for enrollment by investigators

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Monitoring

Duration - Up to 3 years

Participants who have stopped imatinib treatment enter a monitoring phase using MRD detection and imaging to track disease recurrence and drug resistance.

Regular imaging and blood tests for MRD detection as scheduled by the study team

Trial Site Locations

Total: 1 location

1

Peking University People's Hospital

Beijing, Beijing Municipality, China, 100044

Actively Recruiting

Loading map...

Research Team

Z

Zhidong Gao, MD

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

A Phase 2 Study of 5 Years of Adjuvant Imatinib in Patients ...

Gastrointestinal Stromal Tumors

Actively Recruiting

1 location

A Prospective, Multicenter Cohort Study on the Efficacy and ...

Gastrointestinal Stromal Tumors

Actively Recruiting

1 location

A Multicenter Observational Study of Avapritinib in Patients...

Gastrointestinal Stromal Tumors

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Primary Jejunal Gastrointestinal Stromal Tumor: Diagnosis Delay of 3 Years but Successful Management in Early Stage (II) by Surgery and Adjuvant Therapy.

Ferdous Ara Begum, Md Arifur Rahman, Hashim Rabbi...

https://pubmed.ncbi.nlm.nih.gov/31602375

Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall...

https://pubmed.ncbi.nlm.nih.gov/32469385

Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.

Chandrajit P Raut, N Joseph Espat, Robert G Maki...

https://pubmed.ncbi.nlm.nih.gov/30383140

Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions.

Yoon-Koo Kang, Hyung-Don Kim, Hyun Jin Kim...

https://pubmed.ncbi.nlm.nih.gov/36884149

The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients.

Florent Mouliere, Alain R Thierry

https://pubmed.ncbi.nlm.nih.gov/22594497